Vaccine-induced cytotoxic T lymphocytes against human immunodeficiency virus type 1 using two complementary in vitro stimulation strategies

Vaccine

Volumn 18, Issue 9-10, 1999, Pages 835-849

  Gorse, Geoffrey J ^a,b   Patel, Gira B ^b   Mandava, Mahendra D ^b   Belshe, Robert B ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cellular immunity; Cytotoxic T lymphocytes; HIV 1 vaccines

Indexed keywords

ALVAC HIV; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; UNCLASSIFIED DRUG;

ARTICLE; CELLULAR IMMUNITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DOUBLE BLIND PROCEDURE; DRUG SAFETY; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNIZATION; IMMUNOGENICITY; IN VITRO STUDY; INTRAMUSCULAR DRUG ADMINISTRATION; MULTICENTER STUDY; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AIDS VACCINES; ANIMALS; ANTIGENS, CD8; AVIPOXVIRUS; CHO CELLS; CRICETINAE; DRUG THERAPY, COMBINATION; GENE PRODUCTS, ENV; GENE PRODUCTS, GAG; GENE PRODUCTS, NEF; GENE PRODUCTS, POL; GENETIC ENGINEERING; GENETIC VECTORS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; IMMUNIZATION, SECONDARY; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, SYNTHETIC;

EID: 0032703781     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(99)00323-0     Document Type: Article

References (49)

1. Borrow P., Lewicki H., Hahn B.H., Shaw G.M., Oldstone M.B.A. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J. Virol. 68:1994;6103-6110.
2. Musey L., Hughes J., Schacker T., Shea T., Corey L., McElrath M.J. Cytotoxic-T-cell responses, viral load and disease progression in early human immunodeficiency virus type 1 infection. N. Engl. J. Med. 337:1997;1267-1274.
3. Oldstone M.B.A. HIV versus cytotoxic T lymphocytes: the war being lost. N. Engl. J. Med. 337:1997;1306-1308.
4. Ogg G.S., Jin X., Bonhoeffer S., Dunbar P.R., Nowak M.A., Monard S., Segal J.P., Cao Y., Rowland-Jones S.L., Cerundolo V., Hurley A., Markowitz M., Ho D.D., Nixon D.F., McMichael A.J. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science. 279:1998;2103-2106.
5. Koup R.A., Safrit J.T., Cao Y., Andrews C.A., McLeod G., Borkowsky W., Farthing C., Ho D.D. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol. 68:1994;4650-4655.
6. Harrer T., Harrer E., Kalams S.A., Elbeik T., Staprans S.I., Feinberg M.B., Cao Y., Ho D.D., Yilma T., Caliendo A.M., Johnson R.P., Buchbinder S.P., Walker B.D. Strong cytotoxic T cell and weak neutralizing antibody responses in a subset of persons with stable nonprogressing HIV type 1 infection. AIDS Res. Hum. Retroviruses. 12:1996;585-592.
7. Greenough T.C., Brettler D.B., Somasundaran M., Panicali D.L., Sullivan J.L. Human immunodeficiency virus type 1-specific cytotoxic T lymphocytes (CTL), virus load and CD4 T cell loss: evidence supporting a protective role for CTL in vivo. J. Infect. Dis. 176:1997;118-125.
8. Lubaki N.M., Ray S.C., Dhruva B., Quinn T.C., Siliciano R.F., Bollinger R.C. Characterization of a polyclonal cytolytic T lymphocyte response to human immunodeficiency virus in persons without clinical progression. J. Infect. Dis. 175:1997;1360-1367.
9. Dyer W.B., Ogg G.S., Demoitie M-A., Jin X., Geczy A.F., Rowland-Jones S.L., McMichael A.J., Nixon D.F., Sullivan J.S. Strong human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte activity in Sydney blood bank cohort patients infected with nef-defective HIV type 1. J. Virol. 73:1999;436-443.
10. Rowland-Jones S., Sutton J., Ariyoshi K., Dong T., Gotch F., McAdam S., Whitby D., Sabally S., Gallimore A., Corrah T., Takiguchi M., Schultz T., McMichael A., Whittle H. HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women. Nat. Med. 1:1995;59-64.
11. Rowland-Jones S., Nixon D.F., Aldhous M.C., Gotch F., Ariyoshi K., Hallam N., Kroll J.S., Froebel K., McMichael A. HIV-specific cytotoxic T-cell activity in an HIV-exposed but uninfected infant. Lancet. 341:1993;860-861.
12. Cheynier R., Langlade-Demoyen P., Marescot M-R., Blanche S., Blondin G., Wain-Hobson S., Griscelli C., Vilmer E., Plata F. Cytotoxic T lymphocyte responses in the peripheral blood of children born to human immunodeficiency virus-1-infected mothers. Eur. J. Immunol. 22:1992;2211-2217.
13. Jin X., Roberts C.G.P., Nixon D.F., Cao Y., Ho D.D., Walker B.D., Muldoon M., Korber B.T.M., Koup R.A. the ARIEL Project Investigators. Longitudinal and cross-sectional analysis of cytotoxic T lymphocyte responses and their relationship to vertical human immunodeficiency virus transmission. J. Infect. Dis. 178:1998;1317-1326.
14. Rinaldo C., Huang X-L., Fan Z., Ding M., Beltz L., Logar A., Panicali D., Mazzara G., Liebmann J., Cottrill M., Gupta P. High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1-infected long-term nonprogressors. J. Virol. 69:1995;5838-5842.
15. Riviere Y., McChesney M.B., Porrot F., Tanneau-Salvadori F., Sansonetti P., Lopez O., Pialoux G., Feuillie V., Mollereau M., Chamaret S., Tekaia F., Montagnier L. Gag-specific cytotoxic responses to HIV type 1 are associated with a decreased risk of progression to AIDS-related complex or AIDS. AIDS Res. Hum. Retroviruses. 11:1995;903-907.
16. Lamhamedi-Cherradi S., Culmann-Penciolelli B., Guy B., Ly T.D., Goujard C., Guillet J-G., Gomard E. Different patterns of HIV-1-specific cytotoxic T-lymphocyte activity after primary infection. AIDS. 9:1995;421-426.
17. Goulder P.J.R., Sewell A.K., Lalloo D.G., Price D.A., Whelan J.A., Evans J., Taylor G.P., Luzzi G., Giangrande P., Phillips R.E., McMichael A.J. Patterns of immunodominance in HIV-1-specific cytotoxic T lymphocyte responses in two human histocompatibility leukocyte antigens (HLA)-identical siblings with HLA-A*0201 are influenced by epitope mutation. J. Exp. Med. 185:1997;1423-1433.
18. Cooney E.L., McElrath M.J., Corey L., Hu S.-L., Collier A.C., Arditti D., Hoffman M., Coombs R.W., Smith G.E., Greenberg P.D. Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein. Proc. Natl. Acad. Sci. USA. 90:1993;1882-1886.
19. Hammond S.A., Bollinger R.C., Stanhope P.E., Quinn T.C., Schwartz D., Clements M.L., Siliciano R.F. Comparative clonal analysis of human immunodeficiency virus type 1 (HIV-1)-specific CD4+ and CD8+ cytolytic T lymphocytes isolated from seronegative humans immunized with candidate HIV-1 vaccines. J. Exp. Med. 176:1992;1531-1543.
20. Johnson R.P., Hammond S.A., Trocha A., Siliciano R.F., Walker B.D. Induction of a major histocompatibility complex class I-restricted cytotoxic T-lymphocyte response to a highly conserved region of human immunodeficiency virus type 1 (HIV-1) gp120 in seronegative humans immunized with a candidate HIV-1 vaccine. J. Virol. 68:1994;3145-3153.
21. El-Daher M., Keefer M.C., Reichman R.C., Dolin R., Roberts N.J. Jr. Persisting human immunodeficiency virus type 1 gp160-specific human T lymphocyte responses including CD8+ cytotoxic activity after receipt of envelope vaccines. J. Infect. Dis. 168:1993;306-313.
22. Keefer M.C., McElrath M.J., Weinhold K., Gorse G.J., Mulligan M., Francis D., Panicali D. A phase I trial of vaccinia-env/gag/pol (TBC-3B) given by alternative routes, boosted by rgp120. The 12th World AIDS Conference, Geneva, Switzerland, June 28-July 3. 1998;. (Abstract No. 496/21199).
23. SF-2 recombinant gp120, or both vaccines in seronegative adults. J. Infect. Dis. 177:1998;1230-1246.
24. Belshe R.B., Gorse G.J., Mulligan M.J., Evans T.G., Keefer M.C., Excler J-L., Duliege A-M., Tartaglia J., Cox W.I., McNamara J., Hwang K.L., Bradney A., Montefiori D., Weinhold K.J. Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. AIDS. 12:1998;2407-2415.
25. McElrath M.J., Siliciano R.F., Weinhold K.J. HIV type 1 vaccine-induced cytotoxic T cell responses in phase I clinical trials: detection, characterization and quantitation. AIDS Res. Hum. Retroviruses. 13:1997;211-216.
26. Corey L., McElrath M.J., Weinhold K., Matthews T., Stablein D., Graham B., Keefer M., Schwartz D., Gorse G. Cytotoxic T cell and neutralizing antibody responses to human immunodeficiency virus type 1 envelope with a combination vaccine regimen. J. Infect. Dis. 177:1998;301-309.
27. McMichael A.J., Gotch F.M., Noble G.R., Beare P.A.S. Cytotoxic T cell immunity to influenza. N. Engl. J. Med. 309:1983;13-17.
28. Byrne J.A., Oldstone M.B.A. Biology of cloned cytotoxic T lymphocytes specific for lymphocytic choriomeningitis virus: clearance of virus in vivo. J. Virol. 51:1984;682-686.
29. Quinnan G.V. Jr., Kirmani N., Rook A.H., Manischewitz J.F., Jackson L., Moreschi G., Santos G.W., Saral R., Burns W.H. Cytotoxic T cells in cytomegalovirus infection: HLA-restricted T-lymphocyte and non-T-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone-marrow transplant recipients. N. Engl. J. Med. 307:1982;7-13.
30. Stanhope P.E., Clements M.L., Siliciano R.F. Human CD4+ cytolytic T lymphocyte responses to a human immunodeficiency virus type 1 gp160 subunit vaccine. J. Infect. Dis. 168:1993;92-100.
31. Stanhope P.E., Liu A.Y., Pavlat W., Pitha P.M., Clements M.L., Siliciano R.F. An HIV-1 envelope protein vaccine elicits a functionally complex human CD4+ T cell response that includes cytolytic T lymphocytes. J. Immunol. 150:1993;4672-4686.
32. Orentas R.J., Hildreth J.E.K., Obah E., Polydefkis M., Smith G.E., Clements M.L., Siliciano R.F. Induction of CD4+ human cytolytic T cells specific for HIV-infected cells by a gp160 subunit vaccine. Science. 248:1990;1234-1237.
33. Gorse G.J., Patel G.B., Newman F.K., Mandava M., Belshe R.B. Recombinant gp160 vaccination schedule and MHC HLA types as factors influencing cellular responses to HIV-1 envelope glycoprotein. Vaccine. 13:1995;1170-1179.
34. Fries L.F., Tartaglia J., Taylor J., Kauffman E.K., Meignier B., Paoletti E., Plotkin S. Human safety and immunogenicity of a canarypox-rabies glycoprotein recombinant vaccine: an alternative poxvirus vector system. Vaccine. 14:1996;428-434.
35. Taylor J., Meignier B., Tartaglia J., Languet B., VanderHoeven J., Franchini G., Trimarchi C., Paoletti E. Biological and immunogenic properties of a canarypox-rabies recombinant, ALVAC-RG (vCP65) in non-avian species. Vaccine. 13:1995;539-549.
36. Graham B.S., Keefer M.C., McElrath M.J., Gorse G.J., Schwartz D.H., Weinhold K., Matthews T.J., Esterlitz J.R., Sinangil F., Fast P.E. Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: recombinant glycoprotein (rgp) 120, a randomized, double-blind trial. Ann. Intern. Med. 125:1996;270-279.
37. Evans TG, Keefer MC, Weinhold KJ, Wolff M, Montefiori D, Gorse GJ, Graham BS, McElrath MJ, Clements-Mann ML, Mulligan MJ, Fast P, Walker MC, Excler J-L, Duliege A-M, Tartaglia J, the NIAID AIDS Vaccine Evaluation Group. A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with SF-2 rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers. J Infect Dis, 1999;180:290-8.
38. Boyum A. Isolation of mononuclear cells and granulocytes from human blood. Scand. J. Clin. Lab. Invest. 21:(Suppl. 97):1968;77-89.
39. Gorse G.J., Belshe R.B., Newman F.K., Frey S.E. Lymphocyte proliferative responses following immunization with human immunodeficiency virus recombinant gp160. Vaccine. 10:1992;383-388.
40. Tosato G. Generation of Epstein-Barr virus (EBV)-immortalized B cell lines. Coligan J.E., Kruisbeek A.M., Margulies D.H., Shevach E.M., Strober W. Current protocols in immunology. 1991;7.22.1-7.22.3 John Wiley and Sons, New York.
41. Ferrari G., King K., Rathbun K., Place C.A., Packard M.V., Bartlett J.A., Bolognesi D.P., Weinhold K.J. IL-7 enhancement of antigen-driven activation/expansion of HIV-1-specific cytotoxic T lymphocyte precursors (CTLp). Clin. Exp. Immunol. 101:1995;239-248.
42. Smith S.D., Shatsky M., Colien P.S., Warnke R., Link M.P., Gladner B.E. Monoclonal antibody and enzymatic profiles of human malignant T lymphoid cells and derived cell lines. Cancer Res. 44:1984;5657-5660.
43. Ferrari G., Berend C., Ottinger J., Dodge R., Bartlett J., Toso J., Moody D., Tartaglia J., Cox W.I., Paoletti E., Weinhold K.J. Replication-defective canarypox (ALVAC) vectors effectively activate anti-human immunodeficiency virus-1 cytotoxic T lymphocytes present in infected patients: Implications for antigen-specific immunotherapy. Blood. 90:1997;2406-2416.
44. Carmichael A., Jin X., Sissons P., Borysiewicz L. Quantitative analysis of the human immunodeficiency virus type 1 (HIV-1)- specific cytotoxic T lymphocyte (CTL) response at different stages of HIV-1 infection: differential CTL responses to HIV-1 and Epstein-Barr virus in late disease. J. Exp. Med. 177:1993;249-256.
45. Koup R.A., Pikora C.A., Luzuriaga K., Brettler D.B., Day E.S., Mazzara G.P., Sullivan J.L. Limiting dilution analysis of cytotoxic T lymphocytes to human immunodeficiency virus gag antigens in infected persons: in vitro quantitation of effector cell populations with p17 and p24 specificities. J. Exp. Med. 174:1991;1593-1600.
46. McFarland E.J., Harding P.A., Luckey D., Conway B., Young R.K., Kuritzkes D.R. High frequency of gag- and envelope-specific cytotoxic T lymphocyte precursors in children with vertically acquired human immunodeficiency virus type 1 infection. J. Infect. Dis. 170:1994;766-774.
47. Klein M.R., van Baalen C.A., Holwerda A.M., Kerkhoff Garde S.R., Bende R.J., Keet I.P.M., Eeftinck-Schattenkerk J.-K.M., Osterhaus A.D.M.E., Shuitemaker H., Miedema F. Kinetics of gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics. J. Exp. Med. 181:1995;1365-1372.
48. Johnson R.P., Trocha A., Yang L., Mazzara G.P., Panicali D.L., Buchanan T.M., Walker B.D. HIV-1 gag-specific cytotoxic T lymphocytes recognize multiple highly conserved epitopes: fine specificity of the gag-specific response defined by using unstimulated peripheral blood mononuclear cells and cloned effector cells. J. Immunol. 147:1991;1512-1521.
49. Wagner R., Leschonsky B., Harrer E., Paulus C., Weber C., Walker B.D., Buchbinder S., Wolf H., Kalden J.R., Harrer T. Molecular and functional analysis of a conserved CTL epitope in HIV-1 p24 recognized from a long-term non-progressor: constraints on immune escape associated with targeting a sequence essential for viral replication. J. Immunol. 162:1999;3727-3734.